Equities Analysts Offer Predictions for CAPR Q1 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Capricor Therapeutics in a research report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($0.35) per share for the quarter. HC Wainwright has a "Buy" rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics' Q3 2025 earnings at $0.94 EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at ($0.61) EPS.

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $34.50.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR traded down $1.36 during trading on Monday, hitting $11.82. The company's stock had a trading volume of 1,961,525 shares, compared to its average volume of 1,392,917. The company has a market capitalization of $537.46 million, a PE ratio of -11.15 and a beta of 4.10. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The business has a 50 day moving average price of $14.08 and a two-hundred day moving average price of $14.82.

Remove Ads

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CAPR. Farallon Capital Management LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at $31,056,000. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after purchasing an additional 700,243 shares during the period. Woodline Partners LP acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $8,693,000. Altium Capital Management LLC lifted its stake in Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after buying an additional 429,000 shares during the last quarter. Finally, Black Diamond Financial LLC purchased a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $3,833,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.